Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Quotes and News

Regeneron Pharmaceuticals, Inc. (REGN) 261.58 -3.68

Price Open:	264.26	Day's Range:	136.44000 - 283.87000
Price Close:	263.64	52wk Range:	49.58 - 283.87000
Price Day Change:	-3.68	Volume:	804,776
Price % Change:	-1.40	Market Cap:	25.184B
Bid:	254.18000	PE Ratio:	35.25
Ask:	261.58000	EPS Diluted:	7.479

Trade REGN NOW!

The Latest On REGN

Sanofi, Regeneron Announce Patient Enrollment in Two Phase 3 Sarilumab Trials for Rheumatoid Arthritis 5/15/13 5:55am

Short Interest in Vertex Rises, in Celgene Falls 5/11/13 10:45am

UPDATE: Jefferies Raises PT on Regeneron Pharmaceuticals Following Top-Line Q1 Beat 5/6/13 12:50pm

Market Wrap for Friday, May 3: Stocks Jump on Strong Jobs Data 5/3/13 4:28pm

A Peek Into The Market Before The Trading Starts 5/3/13 7:06am

Regeneron Acquires Rights to Two Families of Novel Antibodies 5/3/13 6:41am

Regeneron Pharmaceuticals: The Stock That Only Goes Up? 5/1/13 4:42pm

Market Wrap for Wednesday, May 1: Stocks Fall as Employment Data Weakens in April 5/1/13 4:16pm

UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals Following Cardiologist/Lipidologist Survey 5/1/13 9:35am

Stocks to Watch for April 30, 2013 4/30/13 9:31am

Short Sellers Move into Celgene, Regeneron 4/26/13 1:25pm

Short Sellers Move Out of Amgen, Celgene, Pharmacyclics 4/10/13 1:30pm

Press Releases

Critical Alerts For SanDisk, Computer Sciences, American Tower Corp, Questcor Pharmaceuticals, and Regeneron Pharmaceuticals Released By InvestorsObserver 5/15/13 Newswire

Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA) 5/15/13 Newswire

Regeneron Reports First Quarter 2013 Financial and Operating Results 5/3/13 Newswire

Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs 5/3/13 Newswire

Regeneron Announces Upcoming 2013 Investor Conference Presentations 4/18/13 Newswire

Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013 4/11/13 Newswire

Regeneron Pharmaceuticals Announces Expansion in New York's Hudson Valley 4/4/13 Newswire

BioMed Realty To Develop 297,000 Square Feet In New York Fully Leased To Regeneron Pharmaceuticals 4/4/13 Newswire

Regeneron Announces Potential Additional Royalty Stream Related to EU Approval for Ilaris® (canakinumab) in Patients Suffering Acute Gouty Arthritis Attacks Who Cannot Gain Relief From Current Treatments 3/4/13 Newswire

Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis 3/2/13 Newswire

Regeneron and Bayer Initiate Phase 3 Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia 2/19/13 Newswire

Regeneron Reports Fourth Quarter and Full Year 2012 Financial and Operating Results 2/14/13 Newswire

Get the latest REGN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Regeneron Pharmaceuticals, Inc. stock price.

Partner Headlines

IBD 50 Stocks Delivering Strong Earnings, Sales Gains 5/17/13

Sanofi/REGN Commence Enrollment - Analyst Blog 5/15/13

Stocks End Mixed In Quiet Trade; Stratasys Leads 3D Rally 5/13/13

Regeneron's Eylea Drives Astounding Q1 Results 5/10/13

Regeneron Leads Top 5 Big Cap Stocks By Sales Growth 5/8/13

Midcaps Double S&P 500 Return: Get the Right ETF 5/7/13

Leading Biotechs Act Well But Be Careful Not To Chase 5/6/13

Stocks Up In Afternoon; United Rentals Tops Buy Point 5/6/13

Regeneron Q1 Earnings Soar 5/3/13

Some IBD 50 Stocks Break Out, Others Near Buy Points 5/3/13

Regeneron Profit Skyrockets As Eylea Goes Blockbuster 5/3/13